JNJ · Insider Trading
Johnson & Johnson
Every open-market purchase and sale reported by JNJ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Eugene A. Woods | Director | A | +135 deriv. | — |
| 2026-09-10 | Daniel E Pinto | Director | A | +113 deriv. | — |
| 2026-09-10 | Marillyn A Hewson | Director | A | +180 deriv. | — |
| 2026-09-04 | Timothy Schmid | EVP, WW Chair, MedTech | MIXED | — | −$4.36M |
| 2026-08-18 | Jennifer L Taubert | EVP, WWC. Innovative Medicine | MIXED | — | −$2.22M |
| 2026-08-14 | Joaquin Duato | CEO and Chairman of the Board | MIXED | — | −$17.94M |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell | −48,480 | −$12.52M |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | MIXED | −6,574 | −$2.86M |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell | −48,480 | −$12.52M |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | MIXED | −6,574 | −$2.86M |
| 2026-07-21 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | — | −$2.78M |
| 2023-07-27 | William Hait | See Remarks | MIXED | — | −$1.20M |
| 2023-07-27 | Peter Fasolo | Exec VP, Chief HR Officer | Sell | −20,000 | −$3.41M |
| 2023-06-14 | Kathryn E Wengel | EVP, Chief TO and Risk Officer | Sell | −12,465 | −$1.99M |
| 2023-06-08 | Marillyn A Hewson | Director | A | +230 deriv. | — |
| 2023-05-25 | Joseph J Wolk | Exec VP, CFO | G | −55 | — |
| 2023-05-02 | Darius Adamczyk | Director | A | +1,193 deriv. | — |
| 2023-05-02 | D Scott Davis | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Mary C Beckerle | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Jennifer A Doudna | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Hubert Joly | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Mark B. McClellan | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Marillyn A Hewson | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Paula A Johnson | Director | A | +1,429 deriv. | — |
| 2023-05-02 | Anne M Mulcahy | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Mark A Weinberger | Director | A | +1,193 deriv. | — |
| 2023-05-02 | Nadja West | Director | A | +1,193 deriv. | — |
| 2023-05-02 | John C Reed | EVP, Pharmaceuticals R&D | A | +75,765 deriv. | — |
| 2023-03-09 | Marillyn A Hewson | Director | A | +233 deriv. | — |
| 2023-03-09 | A. Eugene Washington | Director | A | +201 deriv. | — |
| 2023-03-08 | James D. Swanson | See Remarks | Sell | −1,061 | −$164.20K |
| 2023-02-15 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | +2,541 | −$233.29K |
| 2023-02-15 | Elizabeth Forminard | Executive VP, General Counsel | MIXED | +1,631 | −$149.70K |
| 2023-02-15 | Robert J Decker | VP Corporate Controller | MIXED | +1,054 | −$64.32K |
| 2023-02-15 | Joaquin Duato | CEO and Chairman of the Board | MIXED | +17,720 | −$2.20M |
| 2023-02-15 | Peter Fasolo | Exec VP, Chief HR Officer | MIXED | +6,703 | −$933.99K |
| 2023-02-15 | William Hait | See Remarks | MIXED | +5,054 | −$742.98K |
| 2023-02-15 | Ashley McEvoy | EVP, WW Chair, MedTech | MIXED | +10,836 | −$1.16M |
| 2023-02-15 | Thibaut Mongon | Exec VP, WW Chair, Cons Health | MIXED | +7,280 | −$1.04M |
| 2023-02-15 | James D. Swanson | See Remarks | MIXED | +2,310 | −$148.73K |
| 2023-02-15 | Jennifer L Taubert | EVP, WW Chair, Pharmaceuticals | MIXED | +10,853 | −$1.71M |
| 2023-02-15 | Kathryn E Wengel | EVP, Chief TO and Risk Officer | MIXED | +5,948 | −$792.39K |
| 2023-02-15 | Joseph J Wolk | Exec VP, CFO | MIXED | +12,115 | −$1.39M |
| 2023-02-14 | James D. Swanson | See Remarks | MIXED | +903 | −$62.89K |
| 2023-02-14 | Peter Fasolo | Exec VP, Chief HR Officer | MIXED | +1,317 | −$123.34K |
| 2023-02-14 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | +995 | −$96.76K |
| 2023-02-14 | Robert J Decker | VP Corporate Controller | MIXED | +390 | −$30.96K |
| 2023-02-14 | Thibaut Mongon | Exec VP, WW Chair, Cons Health | MIXED | +1,459 | −$133.88K |
| 2023-02-14 | William Hait | See Remarks | MIXED | +2,457 | −$226.75K |
| 2023-02-14 | Elizabeth Forminard | Executive VP, General Counsel | MIXED | +642 | −$61.59K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board | 379,300 | $100.06M |
| Jennifer L Taubert | EVP, WWC. Innovative Medicine | 209,451 | $55.26M |
| Vanessa Broadhurst | EVP, Global Corp Affairs | 34,132 | $9.00M |
| Elizabeth Forminard | EVP, Chief Legal Officer | 32,912 | $8.68M |
| Timothy Schmid | EVP, WW Chair, MedTech | 25,493 | $6.73M |
| Marillyn A Hewson | Director | 3,000 | $791.43K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JNJ quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.